<PAGE>
EXHIBIT 99.1
SHEFFIELD'S CURRENT PRODUCT PIPELINE
<TABLE>
<CAPTION>
PRODUCT NON-CLINICAL CLINICAL
----------------------------------------------------------------------------------------------------------------------------------
FORMULATION PILOT STUDIES IND PHASEI/IIA PHASE IIB PHASE III
------------------ ----------------- ----- --------------- --------------- ---------
<S> <C> <C> <C> <C> <C> <C>
Respiratory:
MSI - albuterol ------------------------------------------------------------------------------------- (To begin
Q2'01)
MSI - ipratropium -------------------------------------------------------------------- (To begin
Q1'01)
MSI - cromolyn --------------------------------------------- (To begin
Q1'01)
MSI - Nano-steroid ------------------------------------- (To be filed
Q1'01)
Unit-dose-Nano-steroid ------------------------------------- (To be filed
Q4'01)
ADDS - Nano-steroid ------------------------------------- (To be filed
Q1'01)
ADDS - respiratory ------------------------------------- (To be filed
product Q1'01)
Systemic:
MSI - morphine -------------------------------------- (To be outlicensed in FY2001)
ADDS - ergotamine -------------------------------------- (To be outlicensed in FY2001)
</TABLE>
<PAGE>
UPCOMING PRODUCT DEVELOPMENT MILESTONES
REMAINDER OF 2000 FIRST HALF OF 2001
----------------- ------------------
. Conduct MSI-albuterol (adult) End of . Initiate MSI-albuterol Phase III
Phase II Meeting with FDA adult trial
. Complete MSI-albuterol Phase I/IIa . Complete MSI-ipratropium Phase IIb
pediatric trial trial
. File IND for Unit Dose-nanosteroid . File IND and complete MSI-cromolyn
Phase I/IIa trial
. File IND and complete MSI-
nanosteroid Phase I/IIa trial
. Complete Unit Dose-nanosteroid
Phase I/IIa trial
. File IND and complete ADDS-patent
extension respiratory product
Phase I/IIa trial
<PAGE>
OTHER UPCOMING MILESTONES
REMAINDER OF 2000 2001
----------------- ----
. Initiate program for development of new . Initiate program for development
ADDS-respiratory product of macromolecule/protein delivery
. Initiate program for development of . Acquire access to complementary
additional systemic compound delivery technologies
